Innovent Biologics has unveiled promising early data for a new antibody designed to “reset” the immune system in patients suffering from severe autoimmune conditions. The company presented pre-clinical results for IBI3055, a tri-specific T cell engager for autoimmune diseases, during an oral presentation at the 2026 Immune Resetting: B-Cell Mediated & Beyond Summit in Boston.
The experimental therapy, IBI3055, is engineered to target two different markers on the surface of problematic immune cells—CD19 and B-cell maturation antigen (BCMA)—while simultaneously engaging the CD3 receptor on T cells. By acting as a molecular bridge, the drug directs the body’s own T cells to identify and destroy the B cells and plasma cells that drive many autoimmune attacks.
For patients with B-cell or plasma cell-mediated diseases, the goal is often “immune resetting.” This involves the deep depletion of the cells responsible for producing harmful autoantibodies, allowing the immune system to potentially restart in a more balanced state. While single-target therapies exist, Innovent’s tri-specific approach aims to abandon fewer “escape” cells, potentially leading to more durable clinical benefits.
The Engineering Behind the “1+1+1” Design
From a technical standpoint, IBI3055 utilizes what the company calls a “1+1+1” T-cell engager format. In plain English, In other words the molecule is designed to bind to three distinct targets at once. While potency is critical, the primary challenge with T-cell engagers has historically been safety; if T cells are activated non-specifically, it can lead to severe systemic inflammation.
To mitigate this risk, Innovent incorporated “steric hindrance-based CD3 masking.” This mechanism essentially keeps the T-cell activation component “hidden” or inactive until the antibody successfully binds to its intended targets (CD19 or BCMA). This target-dependent activation is intended to create a safer profile by reducing the likelihood of T cells attacking healthy tissue or triggering a cytokine storm.
According to the data presented in Boston, this design allows IBI3055 to maintain cytotoxicity levels comparable to therapies that only target a single marker, but with the added advantage of being able to eliminate cells regardless of whether they express CD19, BCMA, or both.
Pre-clinical Performance in Animal Models
The company’s findings relied on two primary animal models to demonstrate the drug’s efficacy and safety. In transgenic mouse models expressing human CD19, BCMA, and CD3, IBI3055 achieved “deep depletion” of B cells and plasma cells. This clearance was observed across multiple critical areas, including the peripheral blood, spleen, lymph nodes, and bone marrow.
Crucially, this depletion led to a significant reduction in circulating immunoglobulin levels—the antibodies that cause tissue damage in autoimmune diseases. The study noted that IBI3055 showed greater activity in these models than therapies targeting only CD19 or only BCMA.
Further testing in non-human primates echoed these results. The primates showed profound depletion of the target cells across various bodily compartments and a significant drop in circulating immunoglobulins. Innovent reported that these results were accompanied by favorable safety and tolerability, suggesting the CD3 masking is functioning as intended.
“Significant unmet medical needs remain in autoimmune diseases driven by B cells or plasma cells. There is an urgent need for innovative therapies capable of inducing deep immune cell depletion and immune resetting to deliver durable clinical benefits,” said Dr. Huizhong Xiong, Vice President of Immunology at Innovent. “Such therapies must balance potent efficacy with favorable tolerability. Through protein engineering and CD3 masking, IBI3055 is designed to achieve this balance and provide a safer and more effective treatment option for patients.”
Strategic Context for Innovent Biologics
The development of IBI3055 fits into a broader aggressive expansion by Innovent Biologics, which has transitioned from a regional player into a global biopharmaceutical contender. Founded in 2011, the company is listed on the Hong Kong Stock Exchange (HKEX: 01801) and has already brought 18 products to market.
Innovent’s strategy relies heavily on high-value partnerships with established global giants. The company currently collaborates with over 30 healthcare organizations, including Roche, Sanofi, Takeda, and Eli Lilly. By diversifying its pipeline across oncology, cardiovascular, and autoimmune sectors, Innovent is positioning itself to challenge the dominance of Western pharmaceutical firms in the “immune resetting” space.
| Feature | Mechanism/Result |
|---|---|
| Targets | CD19, BCMA, and CD3 |
| Design | 1+1+1 Tri-specific with CD3 Masking |
| Mouse Model | Deep depletion in blood, spleen, and bone marrow |
| Primate Model | Profound B/plasma cell depletion; favorable safety |
| Primary Goal | Immune resetting for autoimmune diseases |
What Comes Next
While the pre-clinical data is a vital proof-of-concept, IBI3055 must still navigate the rigorous path of human clinical trials. The transition from non-human primates to human subjects is where the “masking” technology will face its true test: determining if the safety profile observed in animals translates to humans without sacrificing the potency required to treat chronic autoimmune conditions.
Innovent currently has five assets in Phase III or pivotal clinical trials and 14 other molecules in early clinical stages. The company has not yet announced a specific date for the first-in-human trials of IBI3055, but the presentation of this data at a major summit typically precedes a formal Investigational New Drug (IND) filing.
Disclaimer: This article is for informational purposes only and does not constitute medical advice or investment recommendations. IBI3055 is an investigational compound and has not been approved for human use by any regulatory agency.
We invite readers to share their thoughts on the potential of tri-specific antibodies in the comments below or share this report with colleagues in the biotech community.
